John M Mascarenas

Based in metropolitan Phoenix, Arizona, BioAccel is a 501(c)(3) nonprofit organization accelerating the development of new bioscience companies and biomedical products by providing entrepreneurs with the training, mentoring, and support they need to succeed in one of the most heavily regulated and strategically important industries: Biomedical technology. - We seek to develop bioscience entrepreneurs – innovators focused on health informatics and medical devices – to their highest and best potential. - Since our inception in 2009, BioAccel has helped to launch 17 companies and has provided education and mentorship for more than 100 Arizona entrepreneurs. - BioAccel’s portfolio companies support an average wage of $71,800 – 61.8 percent over the Arizona average wage of $44,370. - BioAccel’s entrepreneur accelerator programs have resulted in nearly 100 new, high-paying jobs, expansion of Arizona’s biomedical industry base and a growing entrepreneurial and investment community. From our extensive experience in helping bioscience innovators commercialize their bioscience innovations, we know that many entrepreneurs do not have a clear understanding of the commercialization continuum for biomedical technologies. That’s why our workshops and personal guidance include a proof-of-concept program that addresses the challenges of technology commercialization. Our goal is to increase the pipeline of high-potential proof-of-concept projects and assist with the due diligence required to launch successful bioscience companies in Arizona.

Established in 2009 by experienced M&A professionals, Solganick is a middle-market investment bank and mergers and acquistions (M&A) advisory firm focused exclusively on technology services, software, and healthcare IT companies. Cloud, data analytics, AI, and digital transformation are the main focus of the firms transactions. We use data-driven and AI-based research to find buyers and sellers of companies. Our team has completed over $20B in transaction value to date. With over $20B in M&A transactions completed, we impact your goals with efficient transaction origination and execution strategies in order to achieve maximum value for your business. Using a bespoke approach, we provide intelligent, data-driven mergers and acquisitions advisory services to fast-growing and established IT services, software, and healthcare IT companies. We specialize in identifying potential buyers and acquisition targets, structuring deals to maximize client value, and managing negotiations to ensure a smooth transaction process. Leveraging extensive market insights, data-driven research including artificial intelligence, and a wide network of industry connections, the firm provides a comprehensive solution for technology businesses seeking an exit or growth through M&A. Our recent M&A transactions including Nextira/Accenture, eMedApps/Medical Technology Solutions, Visual BI/Atos, Pandera Systems/66 Degrees, and others.

Based in metropolitan Phoenix, Arizona, BioAccel is a 501(c)(3) nonprofit organization accelerating the development of new bioscience companies and biomedical products by providing entrepreneurs with the training, mentoring, and support they need to succeed in one of the most heavily regulated and strategically important industries: Biomedical technology. - We seek to develop bioscience entrepreneurs – innovators focused on health informatics and medical devices – to their highest and best potential. - Since our inception in 2009, BioAccel has helped to launch 17 companies and has provided education and mentorship for more than 100 Arizona entrepreneurs. - BioAccel’s portfolio companies support an average wage of $71,800 – 61.8 percent over the Arizona average wage of $44,370. - BioAccel’s entrepreneur accelerator programs have resulted in nearly 100 new, high-paying jobs, expansion of Arizona’s biomedical industry base and a growing entrepreneurial and investment community. From our extensive experience in helping bioscience innovators commercialize their bioscience innovations, we know that many entrepreneurs do not have a clear understanding of the commercialization continuum for biomedical technologies. That’s why our workshops and personal guidance include a proof-of-concept program that addresses the challenges of technology commercialization. Our goal is to increase the pipeline of high-potential proof-of-concept projects and assist with the due diligence required to launch successful bioscience companies in Arizona.